What is growth hormone deficiency (GHD)?
GHD is a rare disorder in which there is not enough secretion of growth hormone from the anterior pituitary gland. This disorder is estimated to affect 1 in 4,000 to 1 in 10,000 children.
Continuing to build on a history of leadership in GHD care
For more than 25 years, Pfizer has been dedicated to developing treatments, advancing research, and supporting patients with GHD. Our long-standing commitment to the growth hormone community has helped tens of thousands of patients with a variety of growth disorders reach their treatment goals.
Demanding more for patients, caregivers, and the growth hormone community
At Pfizer, our dedication to the growth hormone community has always been focused on addressing the needs of patients and caregivers. We are committed to delivering quality treatment options that are both efficacious and safe.
Over the past 25 years, we have developed different formulations and devices for a variety of patients.
Moving forward, we will seek innovative ways to optimize the treatment of growth disorders without compromising the efficacy and safety that patients and their families have come to trust.
Raising awareness to help overcome gender disparities in diagnosis
Historical trends have shown that boys tend to be diagnosed with GHD twice as often as girls. The underdiagnosis of girls may reflect the belief in many societies that it is acceptable for girls to be short or “petite.”
To ensure that all appropriate patients have
an equal chance to receive the growth hormone
treatment they need, Pfizer is committed to raising
awareness about this diagnostic gender disparity.
As a parent who has had to give numerous shots over the last 12 years, the easier you make it, the better it is all the way around.
Quote heard in market research.
Addressing the evolving needs of patients and their families
Pfizer understands the impact that GHD can have on the lives of patients and caregivers. We recognize that patients can have individual treatment needs and preferences through different phases in life. That's why we remain devoted to exploring ways to better address the evolving needs of patients and caregivers, and support the health care professionals who treat them every day.
Trusted support and strength in numbers
We know nobody can do it all alone. Pfizer recognizes how valuable it is to be supported with the right information and connected to others in the growth hormone community, particularly for those coming to terms with a new diagnosis. Here are just a few of the many nonprofit patient assistance groups that you may find helpful.
These websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.
Human Growth Foundation (HGF)
The HGF is a voluntary, nonprofit organization whose mission is to help children and adults with growth disorders and GHD through research, education, support, and advocacy.
The MAGIC Foundation
The MAGIC Foundation is a charitable, nonprofit organization created to provide support services for the families of children afflicted with a wide variety of chronic and/or critical disorders, syndromes, and diseases that affect a child's growth.
Prader-Willi Syndrome Association (USA)
Prader-Willi Syndrome Association (USA) is an organization of families and professionals working together to raise awareness, offer support, provide education and advocacy, and promote and fund research to enhance the quality of life of those affected by Prader-Willi syndrome.
Turner Syndrome Foundation (TSF)
The TSF is recognized as a nonprofit organization that provides free resources, supports research initiatives, and facilitates education programs to increase professional awareness and enhance medical care of those affected by Turner syndrome.